Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis by Makunde, William H et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Filaria Journal
Open Access Research
Treatment of co-infection with bancroftian filariasis and 
onchocerciasis: a safety and efficacy study of albendazole with 
ivermectin compared to treatment of single infection with 
bancroftian filariasis
William H Makunde*1, Leo M Kamugisha2, Julius J Massaga2, 
Rachel W Makunde3, Zakana X Savael2, Juma Akida2, Fred M Salum2 and 
Mark J Taylor4
Address: 1Bombo Research Field Station, P.O. Box 950, Tanga, Tanzania, 2Amani Medical Research Centre, P.O. Box 4, Amani, Tanzania, 3Bombo 
Regional Hospital, P.O. Box 452, Tanga, Tanzania and 4Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
Email: William H Makunde* - hwmakunde@hotmail.com; Leo M Kamugisha - hwmakunde@hotmail.com; 
Julius J Massaga - hwmakunde@hotmail.com; Rachel W Makunde - hwmakunde@hotmail.com; Zakana X Savael - hwmakunde@hotmail.com; 
Juma Akida - hwmakunde@hotmail.com; Fred M Salum - ; Mark J Taylor - mark.taylor@liv.ac.uk
* Corresponding author    
Abstract
Background: In order to use a combination of ivermectin and albendazole for the elimination of
lymphatic filariasis, it is important to assess the potential risk of increased adverse events in
individuals infected with both lymphatic filariasis and onchocerciasis. We compared the safety and
efficacy of albendazole (400 mg) in combination with ivermectin (150 micrograms/kg), for the
treatment of co-infections of Wuchereria bancrofti and Onchocerca volvulus with single infection of W.
bancrofti.
Methods: The safety study on co-infections was a crossover, double blind design, while for the
single infection of bancroftian filariasis an open design comparing two treatments was used. For co-
infection, one group was allocated a single dose of ivermectin (150 micrograms/kg) plus albendazole
(400 mg) (Group A). The other group received placebo (Group B). Five days later the treatment
regime was reversed, with the Group A receiving placebo and Group B receiving treatment. For
the single bancroftian filariasis infection, one group received a single dose of albendazole (400 mg)
plus ivermectin (150 µg/kg) (Group C) while the other group received a single dose of albendazole
(400 mg) alone (Group D). Blood and skin specimens were collected on admission day, day 0, and
on days 2, 3, and 7 to assess drug safety and efficacy. Thereafter, blood and skin specimens were
collected during the 12 months follow up for the assessment of drug efficacy. Study individuals were
clinically monitored every six hours during the first 48 hours following treatment, and routine
clinical examinations were performed during the hospitalisation period and follow-up.
Results: In individuals co-infected with bancroftian filariasis and onchocerciasis, treatment with
ivermectin and albendazole was safe and tolerable. Physiological indices showed no differences
between groups with co-infection (W. bancrofti and O. volvulus) or single infection (W. bancrofti). The
frequency of adverse events in co-infected individuals was 63% (5/8, Group A, albendazole +
ivermectin) and 57% (4/7, Group B, placebo) and of mild or moderate intensity. In single W.
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bancrofti  infection the frequency of adverse events was 50% (6/12, Group C, albendazole +
ivermectin) and 38% (5/13, Group D, albendazole) and of a similar intensity to those experienced
with co-infection. There were no differences in adverse events between treatment groups. There
was no significant difference in the reduction of microfilaraemia following treatment with
albendazole and ivermectin in groups with single or co-infection.
Conclusion:  Our findings suggest that ivermectin plus albendazole is a safe and tolerable
treatment for co-infection of bancroftian filariasis and onchocerciasis.
Background
Bancroftian filariasis and onchocerciasis are important
causes of clinical disease and progressive disability in the
tropics and subtropics, affecting more than 120 and 17.6
million people respectively [1,2]. In Tanzania, more than
10 million people live in areas endemic for bancroftian
filariasis, and of these 11.7% are affected by the infection
[3]. Eleven foci for onchocerciasis have been established
in Tanzania in which it is estimated 2 million people are
at risk and of these 400,000 are already infected [4]. Stud-
ies conducted in Tanzania showed that bancroftian filaria-
sis is prevalent along the entire coastal belt of the Indian
Ocean, its islands, and in the regions around the Great
Lake [5]. The clinical manifestations of the disease are
hydrocoele, lymphoedema, orchitis, adenolymphangitis
and elephantiasis. The acute and chronic pathologies
caused by these diseases impose a significant impediment
to socio-economic development [6,7].
Chemotherapy is now considered as the most cost-effec-
tive tool to potentially interrupt transmission [8]. The
most common strategy adopted is mass treatment of pop-
ulations with either diethylcarbamazine (DEC) or iver-
mectin. DEC mass distribution has been the main strategy
for lymphatic filariasis control programmes for many
years in endemic areas based on annual or semi-annual
administration [2]. However, DEC is contraindicated in
individuals with onchocerciasis because of potentially
severe treatment adverse reaction [1]. The severity of such
reactions is reduced in ivermectin, which is considered
safe and effective against either disease [1]. Recently
albendazole has been introduced for use in combined
chemotherapy with either ivermectin or DEC as the treat-
ment regime for the global elimination of lymphatic
filariasis [8]. Albendazole combined with either ivermec-
tin or DEC has been demonstrated to effectively clear ban-
croftian microfilaraemia [9]. The new anti-filarial drug
combinations are expected to improve compliance, cover-
age and reduce costs by introducing simple efficient drug
delivery and distribution methods.
In Tanzania, albendazole and ivermectin have been
adopted as the combination treatment for the commu-
nity-based control of bancroftian filariasis. In order to
determine whether this treatment can be used safely and
effectively in areas of co-endemicity with onchocerciasis,
we examined the safety, tolerability, and efficacy of alben-
dazole with ivermectin for the treatment of individuals
with concurrent infections of bancroftian filariasis and




The Ethics Committee of the National Institute for Medi-
cal Research, Tanzania, the Research Ethics Committee of
the Liverpool School of Tropical Medicine, UK and the
Ethics committee of the World Health Organisation
(WHO) approved the study. The clinical trial was con-
ducted from April 1998 to May 1999 in Muheza district,
Tanga, northeastern Tanzania, where bancroftian filariasis
and onchocerciasis co-exist. Candidates for the trial were
selected from rural communities of Maramba "A" and
Mhinduro, which is the first time the co-existence of both
diseases has been reported in the Western Usambara
Mountains. The majority of the inhabitants are Moslems
and their main source of income is farming, petty trade
and animal husbandry. The villages have not previously
been included in control activities against bancroftian
filariasis, onchocerciasis or other helminths.
Fifteen males aged between 15 and 55 years with co-infec-
tion of bancroftian filariasis and onchocerciasis and 25
(11 male and 14 female [age range 15–55]) for single
infection of bancroftian filariasis were recruited (see Trial
Profile, Figure 1). Individuals were screened for inclusion
into the study by finger-prick blood samples (100 µl) for
bancroftian filariasis and by skin snip for onchocerciasis.
Clinical evaluation was conducted at Bombo Regional
Hospital, Tanga. The inclusion criteria for admission into
this study included; apparently healthy individuals aged
between 15 and 55 years, able to give oral consent to par-
ticipate, weighing more than 31 kilograms, have no papu-
lar onchodermatitis and itching, with no history of taking
herbal medication, anthelminthic or anti-filarial drugs
three months prior to recruitment, microfilaria counts of
≥ 100 mf/ml in Wuchereria bancrofti, and/or Onchocerca
volvulus microfilaria counts of ≥ 5 mf/skin snip. Women
were excluded from the co-infection group due to the risk
of inadvertent pregnancy and the potential effects ofFilaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/15
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unforeseen adverse events on the foetus. In the single
infection of bancroftian filariasis women selected for
inclusion were tested for pregnancy.
Clinical examination and laboratory analysis
On admission to the hospital a full medical history was
obtained and a physical examination was carried out prior
to specimen collection. 7 ml of venous blood was col-
lected into tubes containing ethylenediaminetetraacetic
acid (EDTA) as an anti-coagulant between 21:00 and
Trial profile for co-infections of W. bancrofti and O. volvulus and single infection of W. bancrofti Figure 1
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01:00 h. 1 ml of anti-coagulated blood was thoroughly
mixed with 4 ml of normal saline. The suspension was
then passed through a membrane filter (3 µm pore;
Nuclepore) and the trapped microfilariae (mf) counted.
The pre-treatment mf count was calculated in each case by
averaging counts of two samples, one-collected three days
before admission and the other on day 0 before drug
administration at the hospital. The remaining blood spec-
imens were used for biochemical tests to estimate
bilirubin, aspartate amino transferase (AST), and creati-
nine levels and examination of haematological indices,
including total leucocyte count, differential white blood
cell count and haemoglobin. Skin snips were obtained
from the right and left iliac crests using a Walser corneo-
scleral biopsy punch after disinfecting the site with 70%
alcohol. Skin snips were incubated in 0.9% saline over-
night. The following day, specimens were microscopically
examined for parasite identification and quantification.
Blood specimens and skin snips were collected on admis-
sion day, Day 0, and on Day 2, 3, and 7 to assess drug
safety and efficacy. Thereafter, blood specimens and skin
snips were collected during the 12 months follow up for
the assessment of drug efficacy. Study individuals were
clinically monitored every six hours during the first 48
hours following treatment, and routine clinical examina-
tions were performed during the hospitalisation period
and follow-up. Clinical adverse reactions were monitored
and assessed by a scoring method. The individuals were
assigned scores according to the intensity of adverse reac-
tion, thus a score of 0 = no alteration, no adverse reaction
was reported and individuals could perform their usual
daily tasks, 1 = mild alteration, mild adverse reaction
recorded which individuals are aware of and can easily
tolerate and continue with usual daily tasks, 2 = moderate
alteration, moderate adverse reaction which can cause dis-
comfort, interfere with usual daily tasks and require rest
and/or analgesic before continuing with usual tasks, and
3 = severe alteration, severe reactions which would pre-
vent usual daily tasks and require hospitalisation.
Study protocol
In each sub-study individuals were randomly allocated to
one of the treatment regimens. The study on co-infections
was a crossover, double blind design, while the study on
single infection of W. bancrofti was an open comparison
of the two treatments (see trial profile Figure 1). For co-
infection one group was allocated a single dose of iver-
mectin (150 µg/kg) plus albendazole (400 mg) (Group
A). The other group received 6 saccharine tablets as a pla-
cebo (Group B). Five days later the treatment regime was
administered in reverse, with the Group A receiving pla-
cebo and Group B receiving treatment. For the bancroftian
filariasis infection, one group received a single dose of
albendazole (400 mg) plus ivermectin (150 µg/kg)
(Group C) while the other group received a single dose of
albendazole (400 mg) alone (Group D). Trial drugs plus
placebo were supplied by WHO/CTD, the Carter Centre
(Atlanta, USA) and the Liverpool School of Tropical Med-
icine (Liverpool, UK).
Statistical analysis
Data analysis was done using Epi-Info version 6.04 C and
Stata 6. Geometric mean microfilarial intensity (GMI)
were calculated as antilog [(log (x+1)/n]-1 where x was the
number of mf/ml counted and n is the total number of
individuals. A non-parametric test (Mann-Whitney test)
was used for comparing GMI of different study days and
severity of adverse reactions. Fisher's exact test was used to
compare prevalence of infection. P-values of less than
0.05 were considered to be statistically significance.
Results
Pre-treatment parasitological, physiological, 
haematological and clinical data
Co-infections of W. bancrofti and O. volvulus
The pre-treatment microfilaria counts ranged from 108–
2232 mf/ml in W. bancrofti, and from 5–206 microfilar-
iae/skin snip in O. volvulus. The geometric mean micro-
filarial intensity (GMI) for W. bancrofti, was 378.4 mf/ml
in Group A, and 465.2 mf/ml in Group B. The microfilar-
ial GMI for O. volvulus was 49.1 and 12.9 microfilariae/
skin snips in Groups A and B respectively. There was no
significant difference in terms of mf GMIs in W. bancrofti
in the two treatment regimens (P = 0.7). However, the
geometric mean microfilarial intensity between the two
treatment groups was statistically significant in O. volvulus
(P = 0.02). The physiological and haematological indices
showed no changes for each individual, during the pre-
treatment period or at Day 2/3 or Day 7 in both co-
infected and single infections. Clinically, there was no sig-
nificant variation in blood pressure, both systolic and
diastolic between the treatment groups (data not shown).
Single infection of W. bancrofti
In the single infection the geometric mean microfilarial
intensity in the two-treatment regimens was 508 mf/ml
for each treatment group. There was no significant differ-
ence in geometric mean microfilarial intensity in the two
treatments (P = 0.9).
Post-treatment safety evaluation
Post-treatment levels of the physiological tests and hae-
matological indices in the single and co-infections
between the two treatment regimens, placebo, albenda-
zole alone and the combination of albendazole with iver-
mectin showed no change compared to pre-treatment
levels. Likewise, the other parameters assessed, blood
pressure, heart rate and body weight also showed no
change. The mean level of AST in the co-infections of W.
bancrofti and O. volvulus observed were 18.1 and 27 IU inFilaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/15
Page 5 of 9
(page number not for citation purposes)
Groups A and B respectively. There was no significant dif-
ference in the mean AST levels between Groups A and B (P
= 0.07). The mean AST levels for single infection of ban-
croftian filariasis were 21.9 IU and 23.6 IU for albenda-
zole alone and the combination respectively (P = 0.6).
Adverse Reactions
The adverse reactions occurred at 24 and 48 hours and on
day 6 post-drug administration and were generally mild
and well tolerated (Tables 1 and 2). These effects lasted for
approximately 48 hours. Localised pruritis was observed
in the co-infection of bancroftian filariasis plus onchocer-
ciasis. Adverse reactions such as headache, dizziness and
itching were reported in individuals with single infection
of bancroftian filariasis. In the co-infections 9 out of 15
individuals who experienced adverse reaction, 5 had
received albendazole plus ivermectin whereas 4 received
placebo.
Three individuals in Group A experienced fever, while in
Group B, 3 reported palpitations and one presented
oedema on the right thigh. On day six post-treatment one
individual from the albendazole and ivermectin group
developed painful swelling on the right inguinal gland,
which resolved by the third week post-treatment. In the
single infection of bancroftian filariasis, 11 out of 25 indi-
viduals reported adverse reactions, of which 5 had
received albendazole alone, while 6 had albendazole plus
ivermectin. In the albendazole plus ivermectin group, two
individuals experienced fever and 3 reported generalised
Table 1: Post drug administration adverse events experienced by individuals with co-infections of W. bancrofti and O. volvulus.
Clinical signs / symptoms (score) Peak intensity* Group A† (Albendazole + Ivermectin, n = 
8) (no. of individuals with symptoms)
Group B† (Placebo, n = 7) (no. of 
individuals with symptoms)
Fever 1.0 3 0
Adenitis 2.0 1 0
Oedema 2.0 0 1
Palpitations 1.0 0 3
Pruritis 1.0 1 0
Headache NA 0 0
Dizziness NA 0 0
Itching NA 0 0
Chills NA 0 0
Lethargy NA 0 0
Table 2: Post-drug administration adverse events experienced by individuals with single infection of W. bancrofti
Clinical / Symptoms (Score) Peak intensity* Group C (Albendazole + 
Ivermectin, n = 12) (no. of 
individuals with symptom)
Group D (Albendazole, n = 13) 
(no. individuals with symptom)
Fever 1.0 2 0
Itching 1.0 3 0
Palpitation 1.0 1 0
Headache 1.0 0 1
Dizziness 2.0 0 2
Adenitis 2.0 0 1
Oedema 2.0 0 1
Chills NA 0 0
Lethargy NA 0 0
Myalgia NA 0 0
Anorexia NA 0 0
Scores 0 = no alteration 1 = mild alteration, individual could conduct normal activities without symptom relief. 2 = moderate alteration, individual 
could proceed with normal daily activity after taking analgesic to alleviate events 3 = severe alteration, individual need be admitted hospital and 
treated for symptoms. *Mean of highest reaction score for each individual with this sign/symptom. 0, indicates normal, 1 indicates mild; 2 moderate; 
3 severe, while fever: 0, indicates 37.0°C – 37.4°C, 1, indicates 37.5°C–37.7°C, 2 indicates 37.8°C–38.8°C, 3 indicates >38.8°C † Group A initially 
received a single dose of ivermectin (150 µg/kg) plus albendazole (400 mg). Group B received 6 saccharine tablets as a placebo. Five days later the 
treatment regime was administered in reverse, with the Group A receiving placebo and Group B receiving treatment.Filaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/15
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itching and 1 had palpitations. Of those who received
albendazole alone, one individual reported frontal head-
ache, 2 dizziness, 1 adenitis and another 1 oedema of the
right arm. Adverse reaction intensity mean score for the
single regimen of albendazole alone and the combination
of albendazole plus ivermectin in both co-infected and
single infection was 1 (mild).
Treatment efficacy
Co-infections of W. bancrofti and O. volvulus
The treatment of co-infection with albendazole and iver-
mectin resulted in a rapid reduction of microfilarial inten-
sity over the first week. For O. volvulus and W. bancrofti this
reduction was sustained throughout the 12 months of the
follow up period (Figure 2 & Figure 2b). Microfilarial
prevalence of O. volvulus and W. bancrofti was reduced to
13 and 6% respectively at 14 days post treatment but
increased throughout the rest of the follow up ranging
from 33–53% for O. volvulus and 40–67% for W. bancrofti
(Figure 2c).
Single infection
Treatment of single W. bancrofti infection with albenda-
zole resulted in a sustained reduction of microfilarial
intensity throughout the follow up period (Figure 3a).
The addition of ivermectin significantly improved efficacy
at the time points sampled (P < 0.05 for all time points).
The prevalence of microfilaraemia showed a dramatic dif-
ference between treatment with albendazole and albenda-
zole plus ivermectin. Treatment with albendazole alone
resulted in a 15–38% reduction in prevalence, compared
to reductions of 73–100% in combined treatments (Fig-
ure 3b).
There was no significant difference between single and co-
infected individuals in the GMI of W. bancrofti during
albendazole and ivermectin treatment.
Discussion
This is the first hospital-based trial of a combination of
ivermectin and albendazole for the treatment of co-infec-
tion of bancroftian filariasis and onchocerciasis. We
found that 400 mg of albendazole plus 150 µg/kg of iver-
mectin were safe and tolerable in individuals co-infected
with W. bancrofti and O. volvulus infections. Due to the rel-
atively low numbers of individuals with co-infection in
this endemic area, only a small number of patients could
be recruited to the study. Monitoring of haematological
indices and physiological functions for liver, heart, mus-
cle, kidney and blood showed no alteration as a result of
any treatment regimen. There was no significant variation
in AST levels during pre-and post-treatment for both co-
infected and single W. bancrofti infected individuals in
both treatment regimens. The absence of clinical response
to treatment may be associated with the lower dosages
administered in the current trial as compared to previous
studies where higher doses were used, leading to transient
elevation of the enzymes and increased frequency and
intensity of adverse reaction [10].
Adverse reactions to treatment in patients with co-infec-
tion were equivalent to those experienced in individuals
with single infection and were categorised as mild. The
low frequency and intensity of adverse reactions observed
in the study individuals probably reflects the low intensity
of infections. Quantitatively it has been shown that the
intensity of these adverse reactions is proportional to the
pre-treatment microfilarial density [9] and is associated
with the release of Wolbachia  endosymbionts into the
blood [11,12]. These results are consistent with the con-
clusions from a multi-study analysis of the safety of two
drug regimens for the treatment of lymphatic filariasis
[13] and onchocerciasis [14].
In co-infected individuals albendazole and ivermectin
treatment produced a reduction in microfilarial levels
over the first week of treatment for both O. volvulus and
W. bancrofti. Thereafter microfilarial levels were sustained
at a low level throughout the follow-up period. Prevalence
of infection ranged from 33–53% for O. volvulus and 40–
67% for W. bancrofti from 30–360 days after drug
administration.
In individuals with a single infection of bancroftian
filariasis a similar trend was seen, with a rapid clearance
within a week in the albendazole and ivermectin group.
Treatment with albendazole and ivermectin was signifi-
cantly better than treatment with albendazole alone.
Reduction in the prevalence of detectable microfilaraemia
was observed to be greater in the combination of ivermec-
tin and albendazole (~70–80%) compared to albenda-
zole alone (~20–40%).
Previous studies have shown that 3–6 months post-treat-
ment with ivermectin, when doses of 150 µg/kg or lower
are given, mf do gradually return to pre-treatment levels.
This is probably due to the lack of adulticidal activity and
the transient effect of the drug on embryogenesis [14].
Albendazole alone can have some marginal adulticidal
activity and is moderately microfilaricidal, particularly at
high doses [10]. However, it is the effectiveness of these
drugs in combination, which has led to their use in com-
munity-based control strategies [9].
The dosage tested in this trial has been adopted for the
community-based treatment of W. bancrofti in Tanzania.
It has been observed in a study in Ghana using a similar
dose, that in single bancroftian infections combinations
of ivermectin and albendazole show no significant
improvement on ivermectin alone, with albendazole onFilaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/15
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Co-infected individuals treated with albendazole and ivermectin. a – Geometric mean intensity (95% confidence intervals) of  W. bancrofti microfilariae in co-infected individuals treated with albendazole and ivermectin Figure 2
Co-infected individuals treated with albendazole and ivermectin. a – Geometric mean intensity (95% confidence intervals) of 
W. bancrofti microfilariae in co-infected individuals treated with albendazole and ivermectin. b – Geometric mean intensity 
(95% confidence intervals) of O. volvulus microfilariae in co-infected individuals treated with albendazole and ivermectin. c – 
Microfilarial prevalence (%) in co-infected individuals treated with albendazole and ivermectin.Filaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/15
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Single infections treated with albendazole or ivermectin. a – Geometric mean intensity (95% confidence intervals) of W. ban- crofti microfilariae in single infections treated with albendazole or albendazole and ivermectin Figure 3
Single infections treated with albendzole or ivermectin. a – Geometric mean intensity (95% confidence intervals) of W. bancrofti 
microfilariae in single infections treated with albendazole or albendazole and ivermectin. b – Prevalence of microfilariaemia (%) 
in single infections of W. bancrofti treated with albendazole or albendazole and ivermectin.Filaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/15
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its own showing only minor effects [15]. In another study
in Haiti, combination of albendazole and ivermectin was
more effective than treatment with ivermectin only [16].
Our study shows that albendazole and ivermectin is more
effective than albendazole alone in the reduction of
microfilarial intensity and prevalence. As the interruption
of transmission is fundamental to the success of commu-
nity-based treatments, this emphasises the need for sus-
tained treatments with high community coverage if
transmission is to be interrupted.
In Tanzania, the use of combinations of albendazole and
ivermectin has been adopted as the strategy for the com-
munity-based elimination of lymphatic filariasis as a pub-
lic health problem. The current study suggests that this
combination is safe to be used in areas of co-endemicity
with onchocerciasis.
Conclusions
In areas of co-infection of bancroftian filariasis and
onchocerciasis, which in Tanzania includes approxi-
mately half a million people infected with O. volvulus, the
use of albendazole (400 mg) and ivermectin (150 µg/kg)
appears to be safe and tolerable. Since only a relatively
small number of patients could be recruited to this study
due to the low prevalence of co-infection, these results
should be considered as preliminary and additional stud-
ies on individuals with co-infection in other endemic
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